Literature DB >> 11914410

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

N Schuff1, A A Capizzano, A T Du, D L Amend, J O'Neill, D Norman, J Kramer, W Jagust, B Miller, O M Wolkowitz, K Yaffe, M W Weiner.   

Abstract

BACKGROUND: Both AD and normal aging cause brain atrophy, limiting the ability of MRI to distinguish between AD and age-related brain tissue loss. MRS imaging (MRSI) measures the neuronal marker N-acetylaspartate (NAA), which could help assess brain change in AD and aging.
OBJECTIVES: To determine the effects of AD on concentrations of NAA, and choline- and creatine-containing compounds in different brain regions and to assess the extent NAA in combination with volume measurements by MRI improves discrimination between AD patients and cognitively normal subjects.
METHODS: Fifty-six patients with AD (mean age: 75.6 +/- 8.0 years) and 54 cognitively normal subjects (mean age: 74.3 +/- 8.1 years) were studied using MRSI and MRI.
RESULTS: NAA concentration was less in patients with AD compared with healthy subjects by 21% (p < 0.0001) in the medial temporal lobe and by 13% to 18% (p < 0.003) in parietal lobe gray matter (GM), but was not changed significantly in white matter and frontal lobe GM. In addition to lower NAA, AD patients had 29% smaller hippocampi and 11% less cortical GM than healthy subjects. Classification of AD and healthy subjects increased significantly from 89% accuracy using hippocampal volume alone to 95% accuracy using hippocampal volume and NAA together.
CONCLUSION: In addition to brain atrophy, NAA reductions occur in regions that are predominantly impacted by AD pathology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914410      PMCID: PMC1851674          DOI: 10.1212/wnl.58.6.928

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease.

Authors:  S A Rombouts; F Barkhof; M P Witter; P Scheltens
Journal:  Neurosci Lett       Date:  2000-05-19       Impact factor: 3.046

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging.

Authors:  N Schuff; F Ezekiel; A C Gamst; D L Amend; A A Capizzano; A A Maudsley; M W Weiner
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

Review 4.  Spatial localization in NMR spectroscopy in vivo.

Authors:  P A Bottomley
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.

Authors:  K Kantarci; C R Jack; Y C Xu; N G Campeau; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E Kokmen; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

6.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases.

Authors:  M C Tierney; R H Fisher; A J Lewis; M L Zorzitto; W G Snow; D W Reid; P Nieuwstraten
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

7.  Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease.

Authors:  A T Du; N Schuff; D Amend; M P Laakso; Y Y Hsu; W J Jagust; K Yaffe; J H Kramer; B Reed; D Norman; H C Chui; M W Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

8.  Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.

Authors:  A A Capizzano; N Schuff; D L Amend; J L Tanabe; D Norman; A A Maudsley; W Jagust; H C Chui; G Fein; M R Segal; M W Weiner
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

9.  Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.

Authors:  F Jessen; W Block; F Träber; E Keller; S Flacke; A Papassotiropoulos; R Lamerichs; R Heun; H H Schild
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

10.  Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy.

Authors:  G Stoppe; H Bruhn; P J Pouwels; W Hänicke; J Frahm
Journal:  Alzheimer Dis Assoc Disord       Date:  2000 Apr-Jun       Impact factor: 2.703

View more
  40 in total

1.  Prediction of conversion from mild cognitive impairment to Alzheimer disease based on bayesian data mining with ensemble learning.

Authors:  R Chen; K Young; L L Chao; B Miller; K Yaffe; M W Weiner; E H Herskovits
Journal:  Neuroradiol J       Date:  2012-03-01

Review 2.  N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.

Authors:  Norbert Schuff; Dieter J Meyerhoff; Susanne Mueller; Linda Chao; Diana Truran Sacrey; Kenneth Laxer; Michael W Weiner
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

3.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy.

Authors:  Yue-Ming Jiang; Li-Ling Long; Xia-Yan Zhu; Hong Zheng; Xue Fu; Shi-Yan Ou; Dong-Lu Wei; Hai-Lin Zhou; Wei Zheng
Journal:  Toxicol Lett       Date:  2008-07-23       Impact factor: 4.372

Review 5.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 6.  Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.

Authors:  Kejal Kantarci; Clifford R Jack
Journal:  NeuroRx       Date:  2004-04

7.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Authors:  Kejal Kantarci; David S Knopman; Dennis W Dickson; Joseph E Parisi; Jennifer L Whitwell; Stephen D Weigand; Keith A Josephs; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

8.  A quantitative meta-analysis of brain glutamate metabolites in aging.

Authors:  David R Roalf; Valerie J Sydnor; Madison Woods; David A Wolk; J Cobb Scott; Ravinder Reddy; Paul J Moberg
Journal:  Neurobiol Aging       Date:  2020-07-21       Impact factor: 4.673

9.  Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Melissa E Murray; Tanis J Ferman; Nirubol Tosakulwong; Timothy G Lesnick; Mandie Maroney-Smith; Matthew L Senjem; Jeffrey Gunter; Glenn E Smith; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-01-08       Impact factor: 4.673

Review 10.  Proton MRS in mild cognitive impairment.

Authors:  Kejal Kantarci
Journal:  J Magn Reson Imaging       Date:  2013-04       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.